Brief: Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results In Phase 2A Trial Of Lp-310 For Oral Lichen Planus
24/09/2024 13:05
Sept 24 (Reuters) - Lipella Pharmaceuticals Inc
LIPO.O :
* LIPELLA PHARMACEUTICALS REPORTS ENCOURAGING EARLY
TOLERABILITY
RESULTS IN PHASE 2A TRIAL OF LP-310 FOR ORAL LICHEN PLANUS
* LIPELLA PHARMACEUTICALS INC - LP-310 TREATMENT WELL
TOLERATED
WITH NO UNPLEASANT TASTE
* LIPELLA PHARMACEUTICALS INC - TRIAL TO CONCLUDE BY
MID-2025,
TOP-LINE DATA BY YEAR-END 2024
Source text for Eikon: ID:nGNX4KmG4g
Further company coverage: LIPO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lipella Pharmaceuticals
See all newsBrief: Lipella Pharmaceuticals Says Bankruptcy Court Approves Sale And Asset Purchase Agreement On June 4
Brief: Lipella Pharmaceuticals Inc. Files Voluntary Petitions For Relief Under Chapter 11
Brief: Lipella Pharmaceuticals Announces Positive Final Results From Phase 2a Study Of LP-10 In Oral Lichen Planus
Brief: Lipella Pharmaceuticals Announces Delisting From Nasdaq Capital Market
U.S. STOCKS ON THE MOVE-Marriott International, Coty, Carlyle Group